MicroRNAs (miRNAs) were discovered more than a decade ago as noncoding, single-stranded small RNAs (B22 nucleotides) that control the timed gene expression pattern in Caenorhabditis elegans life cycle. A number of these evolutionarily conserved, endogenous miRNAs have been shown to regulate mammalian cell growth, differentiation and apoptosis. miRNAs are multispecific by nature. The individual miRNA is capable of modulating the expression of a network of mRNAs that it binds by imperfect sequence complementarity. Human cancers commonly exhibit an altered expression profile of miRNAs with oncogenic (miR-21, miR-106a and miR-155) or tumor-suppressive (let-7, miR-15a/16, miR-34a and miR-143/145) activity. As consistent with the natural function of miRNAs in specifying cellular phenotype, miRNA-based cancer gene therapy offers the theoretical appeal of targeting multiple gene networks that are controlled by a single, aberrantly expressed miRNA. Reconstitution of tumor-suppressive miRNA, or sequence-specific knockdown of oncogenic miRNAs by 'antagomirs,' has produced favorable antitumor outcomes in experimental models. We discuss pending issues that need to be resolved prior to the consideration of miRNA-based experimental cancer gene therapy. These include the need for definitive mRNA target validation, our incomplete understanding of rate-limiting cellular components that impact the efficiency of this posttranscriptional gene-silencing phenomenon, the possibility for nonspecific immune activation and the lack of a defined, optimal mode of delivery.
Introduction
MicroRNAs (miRNAs) are a class of endogenous, small (B22 nucleotides), noncoding RNA molecules that regulate a wide array of developmental and physiologic processes. The first miRNA, lin-4, was discovered in Caenorhabditis elegans by Victor Ambrose, 1 and initially termed an stRNA (short temporal RNA) in view of its chronologically restricted expression, and its role in orchestrating the transition from larval to adult stage gene expression in C. elegans. The second miRNA, let-7, was subsequently identified in a large number of species, including vertebrates. Thousands of miRNAs have now been cloned in higher eukaryotes. 2 These miRNAs are highly conserved across species, and exhibit the common function of negatively regulating gene expression at the posttranscriptional level.
Approximately 450 miRNAs have been identified in mammalian cells, although sequence analysis predicts the presence of up to 1000 different miRNAs. However, only a limited number has been defined functionally through overexpression, misexpression and in vitro knockdown. [3] [4] [5] miRNAs modulate gene expression by utilizing much of the cellular apparatus involved in the phenomenon of RNA interference and perform endogenous functions that were previously assigned exclusively to small interfering RNAs (siRNAs). 6 miRNAs are commonly encoded as polycistronic clusters. Processing by the RNase III enzyme Drosha and its cofactor, Pasha (also known as DGCR8/diGeorge syndrome critical region gene-8) converts the pri-miRNA transcripts into stem-loop (hairpin)-configured, 60-110-nucleotide pre-miRNAs in the nucleus ( Figure 1 ). The pre-miRNA is exported into the cytoplasm by exportin 5 and involves Ran, a GTP-binding cofactor. 7 Another RNase III enzyme, Dicer, cleaves the pre-miRNA into a transient, B22-nucleotide miRNA/ miRNA* duplex intermediate prior to its integration into the miRNA-associated multiprotein RNA-induced silencing complex (miRISC). 8 The miRISC assembly comprises of the Argonaute proteins (AGO2 and AGO1), as well as other proteins (TRBP and PACT) that interact with the Dicer-linked miRNA/miRNA* duplex. Unwinding of the duplex likely involves an ATP-dependent RNA helicase. 9 The antisense strand of the miRNA, retained by the complex by virtue of its pharmacodynamic features, 10 is guided by the miRISC effector complex to complement with the target messenger RNA (mRNA) sequence, forming an A-form double-stranded helix.
11 mRNA target recognition commonly requires a perfect 6-7-nucleotide match at the 5 0 end of the miRNA, known as the 'seed' sequence, and extensive base pairing to the remaining sequence of the miRNA.
12 AGO2, an endonucleolytic component of the miRISC, appears responsible for the cleavage and displacement of the passenger strand (miRNA*), as well as cleavage of the targeted mRNA, which complements perfectly with the miRISC-loaded miRNA. 13, 14 By comparison, mRNAs that binds with imperfect complementarity to the miRNA are subject to translational blockade, likely due to the formation of a bulge sequence in the middle of the A-form helix that is not suitable for RNA cleavage (reviewed in Rana 15 ). Translational repression is considered to be the predominant mechanism in mammalian cells, [16] [17] [18] [19] and requires the general translation repressor protein RCK (also known as p54 20 ), which has a putative role of oligomerizing with the target mRNAs and shuttling them to P-bodies, cytoplasmic foci that serve as depot for storage and/or sequence-specific miRISC processing. 16, 21 Deadenylation and subsequent mRNA degradation constitutes yet another mechanism for the downregulation of mRNA target from imperfectly matched miRNA binding. 22, 23 Effector function through imperfect complementation implies that an individual miRNA can potentially regulate many mRNA targets. 19 Indeed, sequence analysis Figure 1 Biogenesis of mammalian microRNA (miRNA). miRNAs, often encoded as polycistrons, are transcribed into primary miRNA transcripts, then processed by the RNase III enzyme Drosha and its cofactor, Pasha into 60-110-nucleotide pre-miRNA hairpins in the nucleus. The pre-miRNA is exported into the cytoplasm by exportin 5 and its cofactor Ran, where it is cleaved by Dicer into a transient, B22-nucleotide miRNA/miRNA* duplex intermediate. The antisense strand of the miRNA, retained by the complex by virtue of its pharmacodynamic features, is guided by the multiprotein RNA-induced silencing complex (miRISC) effector complex to complement with the target messenger RNA (mRNA) sequence, forming an A-form double-stranded helix. AGO2, an endonucleolytic component of the miRISC, appears responsible for the cleavage and displacement of the passenger strand (miRNA*), as well as endonucleolytic cleavage of the targeted mRNA that binds with the loaded miRNA by perfect sequence complementation. By comparison, mRNAs that bind with imperfect complementarity to the miRNA are subject to translational blockade, likely due to the formation of a bulge sequence in the middle of the A-form helix that hinders the cleavage process.
has identified multiple, eligible binding sites in the 3 0 -UTRs of different mRNAs, hence giving rise to divergent (a single miRNA modulating multiple mRNA targets) and convergent (multiple miRNAs modulating a single mRNA target) paradigms of gene regulation. 10, 12, 24 For example, the 3 0 -UTR of the pivotal angiogenic factor VEGF (vascular endothelial growth factor) contains eligible binding domains for 13 miRNAs, including let-7b, miR-16, miR-17-5p, miR-20a, miR-20b, miR-106a and miR-106b in the nasopharyngeal carcinoma line CNE. To examine the interactive outcome of these miRNAs, Hua et al. 25 have carried out cotransfection studies with the predicted miRNA-binding regions cloned into the 3 0 -UTR of a luciferase reporter gene. miRNAs with distinct binding sites (miR-20a and miR-361) exhibited coordinate, additive suppressive activity, whereas the suppressive activity of one miRNA was usurped by another with an overlapping binding domain (miR-125a and miR-378). As consistent with the divergent paradigm, coregulatory activities were also observed, whereby VEGF-suppressive miRNAs also downregulated other angiogenesis-related genes, including uPAR, COX2 and c-MET. 25 Thus, a relatively small number of miRNA networks can effectively modulate multiple factors involved in angiogenesis.
It is estimated that up to one-third of protein-coding human mRNAs are susceptible to this complex miRNAregulatory network. 26 Genes that are key regulators or essential for cell function may have high rates of transcription and low rates of translation. 27 This 'genetic buffering' effect can be achieved by negative translational modulation by miRNAs, allowing the cell to make many mRNA copies but to have a low and carefully controlled amount of protein. 28 Thus, appropriate actions by an miRNA can achieve rapid changes in protein synthesis without altering transcriptional activity or mRNA processing. A subset of intragenic, intronic miRNAs has been identified recently in mammalian cells to share the same promoter with their encoded target genes. The expression of a gene results not only in the gain of function of that gene but also the coordinate loss of function of other downstream genes with complementarity to the mature intronic miRNA. 29 This mechanism allows for a precise, immediate and rapidly reversible way of controlling expression of proteins. 30 
Altered miRNA expression in human cancers
Multiple mechanisms lead to altered miRNA expression in human cancers, although a majority of studies point to chromosomal aberrations as the primary contributor. Aberrant miRNA expression in human cancers was first described in B-CLL (B-cell chronic lymphocytic leukemia), where hemizygous and/or homozygous chromosomal deletion at the 13q14 locus results in the loss of miR-15 and miR-16 expression. 31, 32 The preponderance of this phenomenon in indolent CLLs and a large proportion of mantle cell lymphomas and multiple myelomas 33 implicate a pathophysiologic role for the loss of miR-15/16 function in these hematopoietic malignancies. [34] [35] [36] Of the 186 miRNA sequences tested by Calin et al., 32 approximately 50% were localized to cancerassociated genomic regions of instability, including fragile sites (FRAs) and human papilloma virus (HPV) integration sites, homeobox (HOX) genes, minimal regions of loss of heterozygosity (LOH) and regions of amplification. The high frequency of genomic alterations in miRNA loci in human cancers was recently confirmed by high-resolution array comparative genomic hybridization analyses. 37 Notably, miR-125b, a homolog of lin-4, is located in a fragile site on chromosome 11q24 and now known to be deleted in a subset of patients with breast, lung, ovarian and cervical cancer ( Table 1) . Chromosomal deletion at 5q32 was seen in colon 71 and breast 51 cancers, accounting for the downregulated expression of the miR-143/145 clusters. Gene copy number changes were believed to be responsible for the altered expression of 41 miRNAs (26 with gains and 15 with losses) in at least 15% of breast and ovarian cancers, and melanoma. 37 Recent findings indicate that epigenetic aberrations, [83] [84] [85] [86] [87] and miRNA processing and degradation defects also affect miRNA expression. [88] [89] [90] [91] About half of the miRNA genes are associated with CpG islands and thus represent candidate targets for the DNA methylation machinery. 87 Methylation status has been correlated with altered levels of miRNAs in a number of recent studies, such as decreased miR-124a expression that was attributed to DNA hypermethylation in colon, breast and lung carcinomas. 85 Conversely, DNA hypomethylation likely led to increased miR-21, -203 and -205 in ovarian cancer cells, 52 and let-7-3a in lung adenocarcinomas. 86 As a whole, miRNA promoters contain a lower percentage of CpG islands as compared with coding gene promoters, suggesting that CpG island modification may play a comparatively less important role in the transcriptional regulation of miRNA.
In spite of normal expression levels of pri-miRNA, a number of human primary cancers displayed reduced levels of mature miRNAs. 88 Thomson and co-workers 88 subsequently localized this discrepancy to a processing defect from the loss of the RNase III Drosha. Conversely, enhanced Drosha activity, through its fusion with the translocated, oncogenic All1 gene, appeared to be responsible for miR-191 upregulation in human leukemias, 89 which in turn contributed to a poor prognostic outcome for acute myeloid leukemias. In a proportion of non-small cell lung cancers (NSCLCs), however, decreased Dicer endonuclease activity, but not Drosha, correlated with reduced let-7 expression, an unfavorable postoperative survival and poor tumor differentiation status. 90 The loss of Dicer likely represents a somatic alteration, as Dicer-deficient mice failed to thrive beyond gastrulation due to the lack of multipotent stem cell development. 91 Another caveat is that these enzymes may perform functions in addition to miRNA processing. 92 Hence, common oncogenetic and epigenetic defects likely impact both coding and noncoding RNA transcription, contributing independently or in concert to the altered expression of miRNAs. Abbreviations: AT1R, angiotensin II type I receptor; Bcl-2, B-cell lymphoma 2; Br, breast; Ce, cervical; Co, colon; CTGF, connective tissue growth factor; E2F1, E2F transcription factor 1; EIF4EBP1, eukaryotic elongation initiation factor 4E binding protein 1; ERK5, extracellular signal-regulated kinase-5; G-protein, guanine nucleotide-binding protein; Gl, glioblastoma; Hp, hepatocellular; c-kit, tyrosine kinase; LATS2, large tumor suppressor homolog 2; LL, leukemia and lymphoma; Ln, lung; miRNA, microRNA; c-myc, myelocytomatosis viral oncogene; NSCLC, nonsmall cell lung cancer; Ov, ovarian; PDCD4, programmed cell death 4 tumor suppressor protein; PLAG1, pleomorphic adenoma gene 1; Pn, pancreatic, Pr, prostate; PTEN, phosphatase and tensin homolog; Raf1, serine/threonine protein kinase; Ras, rat sarcoma viral oncogene homolog; RB-1, retinoblastoma 1; TCF8 (ZEB1, deltaEF1), transcription factor 8; Te, testes; TGFb2R, transforming growth factor beta-2 receptor; Thy: thyroid carcinomas; TP53INP 1, tumor protein p53-induced nuclear protein 1; TPM1, tropomyosin 1; tsp-1, thrombospondin-1.
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Concurrent with studies that define the pivotal role of miRNAs in regulating normal tissue differentiation, highthroughput analyses have been used in determining the miRNA phenotype of human cancers. Lu et al. 38 showed that primary and metastatic lung adenocarcinomas exhibit a unique miRNA expression profile from normal lung, based on liquid-phase array hybridization with 131 miRNA probes. Volinia 66 identified a solid cancer miRNA signature having common features for lung, breast, stomach, prostate, colon and pancreatic tumors, and comprised 43 significantly altered miRNAs that embodied the cancer-associated miRNAs miR-17-5p, miR-20a, miR-21, miR-92, miR106a and miR-155. As consistent with the tissue-specific pattern of miRNA expression, miRNA profiling successfully identified the tissue origin of 15 distinct tumor types with 80% accuracy. 93 Recent studies indicated that miRNA expression profiles correlated with cancer pathophysiological features. Bandres 49 showed that colorectal cancer development was associated with significantly downregulated miR-30c, -124a, -133a and miR-145, and increased expression of 98 miRNAs including the miR-17-92 cluster. Similarly, miRNA expression profiling of 76 primary breast cancer samples have identified an array of dysregulated miRNAs (decreased miR-145 and miR125b, and increased miR-21, -34 and -155) that reflected biopathologic features, including estrogen/progesterone receptor expression, tumor stage, vascular invasion or proliferation index. 51 miR-10b was overexpressed in metastatic breast cancer cells and likely constituted an inducing component for distant metastases. 46 While differential expression of coding mRNA between normal and malignant tissues may differ by orders of magnitude, relatively modest differences (one-to twofold or less) were commonly observed with respect to individual miRNAs, 15, 28, 30 which may account for some conflicting findings regarding the absolute expression level of individual miRNAs. Of the two widely reported highthroughput techniques, the solid-phase, array-based platform is generally considered as semiquantitative, often requiring transcript amplification/labeling and carries an inherent limitation of cross hybridization among miRNAs of the same family. 88, 94, 95 Flow-based, liquid-phase profiling has the theoretical edge of increased specificity in discriminating the expression of closely related miRNAs, 38, 49 but is technically demanding with respect to quality consistency in the production of miRNA probes and the intricacy of the flow analytic processing for reactant subset discrimination. This technique reportedly is more sensitive in detecting modest decreases in downregulated miRNAs. 38, 96 Regardless of the highthroughput platform, independent validation by a second technique such as northern blotting or quantitative, realtime PCR, is de rigueur for confirming miRNA expression profile. Further, the identification of histotype-specific mRNA target and/or affected cellular pathways is critical, to establish the pathophysiologic relevance of the individual, aberrantly expressed miRNAs as related to cancer initiation and progression.
let-7, multiple mRNA targets and impact on patient survival
The term 'oncomir' was coined by Hammond and co-workers 76 to denote miRNAs that are integral to the molecular architecture of oncogene and tumor suppressor networks, and best exemplified by the let-7 miRNA. let-7 is one of the two stRNAs initially discovered in C. elegans. Owing in part to its highly conserved nature even in humans, let-7 was the first miRNA identified in mammalian cells. 97 In C. elegans, let-7 suppresses the expression of let-60, 98 an ortholog of the human RAS family of oncogenes. Indeed, a variety of studies have demonstrated the tumor suppressor role of let-7 in mammalian lung tissues.
39 let-7 expression was consistently reduced by 50% in lung tumors, as compared with adjacent normal tissues. 98 Decreased let-7 expression was an independent prognosticator for poor survival 40 in a retrospective study on 143 cases of surgically resected NSCLCs. Patients with low let-7 expression had a greater risk of earlier death and a hazard ratio of 2.2 as compared with patients with high let-7 expression. Lower expression of let-7 was correlated with a markedly upregulated levels of RAS oncoprotein, another biomarker for poor survival for NSCLC. 99 In vitro studies showed that exogenously introduced let-7a and let-7f, two of the dominant isoforms of the let-7 family, markedly reduced in vitro clonogenicity of the human lung cancer cell line A549, 40 whereas inhibition of let-7 function led to increased cell division in A549 and the hepatoma line HepG2, likely due to a blockade of G 1 /S transition. 39 The loss of let-7 also led to radioresistance in vitro, suggesting that altered let-7 expression likely impacts the response of a cancer cell to treatment. 100 Recently, Karube 101 showed that NSCLCs also displayed decreased Dicer expression. Poorly differentiated tumors exhibited a higher incidence of reduced Dicer expression, and lower Dicer expression was an independent prognostic indicator for surgically treated NSCLC. Hence, one could speculate that cellular dysfunction stemming from an altered let-7 genotype, its 3 0 -UTR miRNA-binding sites, or pathways that process or regulate let-7 expression may contribute critically to lung cancer oncogenesis and disease progression. 47 The cancer growth-suppressive activity of let-7 has since been validated in other human cancers, including colon, 41, 102 hepatocellular, 103 gastric 104 and ovarian cancers. 42 In addition to members of the RAS family, Johnson showed that the cell-cycle regulators CDK6 (cyclin D kinase 6) and CDC25A are also likely, direct targets for let-7, based on differential, high-throughput expression array analysis, in silico target prediction and validation by reporter gene expression analysis in let-7-transfected lung and liver cancer lines. 39 The tumorsuppressive role of let-7 may also come from its binding to miRNA-based cancer gene therapy AW Tong and J Nemunaitis the high-mobility group A2 (hmga2) oncogene. 105 The loss of the let-7-binding/repression elements in the 3 0 -UTR of hmga2 mRNA was associated with the development of abdominal lipomatosis, lymphomas, pituitary adenomas and lung adenomas. The targeting of hmga2 mRNA by let-7 was recently confirmed by expression analysis with the NCI60 panel of human tumor cell lines, where loss of let-7 expression was a marker for less differentiated cancers. 42 For MYC-dysregulated hematopoietic cancers such as Burkitt lymphoma, let-7 expression was inversely correlated with that of the c-myc oncogene mRNA. 43, 106 Transfection with pre-let-7a downregulated myc mRNA and its target genes, and reduced proliferation. These findings illustrate the context dependence of let-7 targets in cancers of different histological types. The tumor-suppressive role of let-7 appears to be directly related to its capacity to modulate multiple oncogenes, including RAS, MYC and HMGA2.
miRNAs target oncogenes and tumor suppressor genes
Evidence is accumulating with regards to the capacity of other aberrantly expressed miRNAs to modulate oncogenic and tumor suppressor activity, hence providing explanations for their pathophysiologic role in human oncogenesis and tumor progression (Table 1 and Figure 2 ).
The target gene for miR-15a and miR-16-1 has been identified to be bcl-2, the archetypical antiapoptotic gene whose activation is considered to be critical for the oncogenic process of human lymphomas, leukemias and lung cancer. The loss of these miRNAs correlated with BCL-2 overexpression, while mir-15/16 reconstitution increased tumor apoptotic activity through their interaction with bcl-2 mRNA. 107 The proto-oncogene c-myc encodes a transcription factor that regulates cell proliferation, growth and apoptosis, whose activity is in turn modulated by miRNAs. The miR-17-92 polycistron, commonly elevated in C-MYC þ human B-cell lymphomas, was found to act in concert with this oncogene to accelerate tumor development in a mouse lymphoma model. 76 For primary neuroblastomas, miR-17-92 cluster (including miR-106a) expression correlated positively with N-MYC amplification. 77 Increased neovascularization in MYC-overexpressing tumors was mediated at least in part through miR-17-92 cluster upregulation, 108 resulting in the downregulation of antiangiogenic proteins with thrombospondin motifs including tsp-1 (thromospondin-1) by miR-19 and the CTGF (connective tissue growth factor) by miR-18. Conversely, miR-17-5 and miR-20a of the miR-17-92 cluster also exhibited tumor suppressor activity through its downregulation of E2F1 or other C-MYC-dependent transcriptional factors. E2F1 is a downstream target gene of c-myc, best known for driving cell-cycle progression in the G1 stage. Other C-MYC target genes (RPS6KA5, BCL-11B, PTEN (phosphatase and tensin homolog) and HCFC2) are also predicted templates for translational regulation by the miR-17-92 cluster. 109 These findings, when contrasted with the oncogenic activity of the miR-17-92 cluster in diffuse large cell lymphoma and B-CLL, indicate that the regulatory roles of miR-17-92 are highly contextural, exerting their influence on cell proliferation and tumorigenesis according to the milieu of target mRNAs that are expressed. 71 A number of solid cancers displayed reduced steadystate expression of the miR-143 and miR-145 cluster, including adenomatous and cancer stage of colorectal neoplasia, breast, prostate, cervical, hepatocellular carcinomas, as well various B-cell malignancies. 71, 72, 44 The tumor-suppressive activity of miR-143 and miR-145 has been demonstrated in vitro, 41 with ERK5 (extracellular signal-regulated kinase-5) identified as the target gene for miR143 in colon cancer DLD-1 41 and Burkitt lymphoma RAJI 72 lines. ERK5, a recently discovered member of the MAPK (mitogen-activated protein kinase) family and downstream mediator of multiple extracellular signals and oncogenes, is a critical component for mitotic entry and for the survival of proliferating cells. 110 Other eligible targets for miR-143/145 71 include MTHFR (methylenetetrahydrofolate reductase), whose variant expression was associated with aberrant DNA methylation patterns in colorectal tumors, 111 and the sodium-and potassiumdependent ATPase A subunit (ATP1A1) shown to be reduced in premalignant mucosa and in colorectal tumors. 112 Hence, the tumor suppressor activity of miR-143 and miR-145 may manifest in a wide array of miRNA-based cancer gene therapy AW Tong and J Nemunaitis pathophysiological functions. It is noteworthy that the hairpin precursor transcripts of miR-143 and miR-145 were not downregulated in colon tumor tissues, 71 suggesting that a disruption in processing may account for the decreased expression of the mature miR-143/145.
The miR-221/222 cluster has been shown to be upregulated in various malignancies of neural crest tissues, including glioblastomas, neuroblastoma with Nmyc amplification and thyroid papillary carcinoma. 78, 70, 79 Earlier studies suggest that miR-221/222 targeted the proto-oncogene/tyrosine kinase receptor c-kit in papillary thyroid cancers, 76, 70, 79 although this finding was not experimentally validated. Three independent studies recently identified experimentally that the multifunctional cyclin-dependent kinase inhibitor and tumor suppressor p27 (kip1) was a direct target of miR-221 in glioblastoma, 78 papillary carcinoma 59 and prostate cancer. 80 The findings of miR-221/222 dependence for tumor survival have prompted the investigation of miR-221/222 inhibitors as a venue for experimental therapy of these tumor cell types. 79 The human proto-oncogene bcl-6 encodes a BTB/POZzinc-finger transcriptional repressor that is necessary for germinal center formation, and is implicated in the pathogenesis of B-cell lymphoma.
113,114 BCL-6 suppresses p53 expression and modulates DNA damage-induced apoptotic responses in germinal center B cells. bcl-6 is a predicted target of miR-127, an miRNA that is part of the miR-136, -431 and -433 cluster. 69 This miRNA cluster is downregulated or completely silenced in the majority of human tumor cell lines. However, DNA demethylation and histone deacetylase inhibition can activate the expression of the tumor-suppressive miR-127, correspondingly downregulating bcl-6.
Intermodulation of miRNAs and tumor suppressor genes
A number of miRNAs have now been shown to serve as effectors for the tumor suppressors p53 and rb. The tumor suppressor gene p53, best known as a key regulator of cell-cycle control and apoptosis, 115 may impact miRNA activity by at least two mechanisms, by functioning as an RNA-binding protein and recruiting miRNA to the actively translated mRNA complex, or as a transcription factor to upregulate miRNAs and downstream cellular mRNAs. 60 Conditional expression of the p53 transgene, or activation of endogenous, wt p53, both led to pronounced upregulation of miR-34a in human cancer cells, indicating that miR-34a is encoded by a p53-responsive gene. 45 Studies by Raver-Shapira, 61 Chang 62 and others 45 showed that miR-34a is a direct transcriptional target of p53 that can mediate the proapoptotic effects of p53. 61 Hence, altered miR-34a expression may contribute to tumorigenesis by attenuating p53-dependent apoptosis.
In the p53 null HCT-116 colon carcinoma line, ectopic wt-p53 expression led to increased expression of 11 miRNAs, including miR-181 and miR-132 with cell proliferation regulatory activities, and miR-21 with antiapoptotic function. 30 miR-21 was also upregulated in glioblastoma cells, 53 and recently found to target the tumor suppressor gene, TPM1 (tropomyosin 1) that modulated human breast cancer cell growth. 54 wt-p53 expression decreased the expression of 43 miRNAs, including miR-15b, miR-125a and miR-191, whereas the loss of wt-p53 expression increased expression of SPIB, a regulator of transcription from Pol II promoter, and translation initiation factor 4A and 5A, which are susceptible to miR-15b and miR-125a modulation. For the H1299 lung cancer line, conditional expression of the p53 wild-type transgene led to increased expression of 34 miRNAs, whose putative silencing targets include E2F3/ NOTCH1/DLL1 (miR-34a), E2F1 (miR-20a, miR-17-5a), BCL-2 (miR-15a and miR-16) SDF-1 and BRN-3b (miR23a). 45 Hence, the loss of tumor suppressor activity from p53 aberrancy may manifest by downstream alterations of multiple miRNAs serving as intermediate effectors for increased cell cycling and decreased apoptotic consequences.
Like p53, the loss of RB1 function impacts cellular differentiation, survival and programed cell death. For colon cancer cells, the lack of RB1 protein expression appears to be a translation defect, in view of normal rb1 transcriptional activity. In gastric, prostate and lung tumor samples, downregulated RB1 has been inversely correlated with the overexpression of miR-106a. 66 miR106a has now been shown to bind to the UTR of rb1 mRNA, 66 reflecting its capacity to regulate RB1 activity posttranscriptionally. Conversely, breast cancers with modestly increased RB1 levels exhibited lower miR106a. 66 The preliminary findings of Lujambio indicated that epigenetic loss of miR-124a was linked with RB phosphorylation and activation of oncogenic CDK6 in human colon cancer cell lines. 67 Thus, miRNAs may act both as effectors or modulators of oncogenes and tumor suppressor genes in controlling cell differentiation and apoptosis.
Theoretical and practical considerations of miRNA-based cancer gene therapy
The presence of functional redundancy in a thriving biologic system, such as cancer, likely buffers the populational impact by any single gene/target modification on the malignant process, with rare exception (for example, chronic myeloid leukemia). 116 However, highly connected targets do allow for 'attack vulnerability.' In other words, the disordered circuitry characteristic of malignancy results in a change, such that the otherwise robust oncogenic process can become, almost paradoxically, more highly dependent on a specific rewired pathway ('pathway addiction'). 116 This thesis forms the theoretic basis of attempting to correct the tumor phenotype through the targeting of the dominant, offending oncogenic pathway.
miRNA-based cancer gene therapy AW Tong and J Nemunaitis miRNA-based cancer gene therapy offers the theoretical alternative of targeting multiple gene networks that are controlled by an individual miRNA, as consistent with the natural function of this class of molecules in specifying cellular phenotype through posttranscriptional modulation. 92 As illustrated by Lim et al., 117 the physiological phenotype of a cell may be balanced on the activity of a limited number of miRNAs. Ectopic expression of miR-124 in the cervical cancer line HeLa shifted gene expression profile toward that of the brain, whereas delivery of miR-1 shifted its gene expression toward that of skeletal muscles. Correspondingly, high endogenous miR-124 and miR-1 expression was found in brain and skeletal muscles, respectively. With respect to hematopoietic differentiation, unilineage erythroid differentiation requires the downregulation of miR-221 and miR-222, two miRNAs that are highly expressed in human cord blood-derived CD34 þ progenitor cells, 118 whereas ectopic expression of miR-181a or miR-223 þ miR-142 was adequate in directing lymphoid progenitor differentiation toward B-or T-cell lineage, respectively. 119 Thus, miRNA-based cancer therapeutics holds the appeal of efficacy and widespread phenotypic ramifications.
Efficacy
MicroRNAs offer the venue of modulating gene expression programs in an immediate and reversible manner, based on their natural function of fine-tuning gene expression at the posttranscriptional level. 30 Reconstitution of downregulated miRNAs offers the theoretical edge of correcting the malignant defect with endogenously occurring molecules of arguably preoptimized binding avidity through natural selection. As discussed in a subsequent section, lessons from the study of ectopically introduced miRNA indicate that relatively small changes in miRNA gene dosage and corresponding gene modifier effects can achieve substantive phenotypic alterations, 92 reinforcing the notion that correction of a limited small number of miRNA-networked transcripts can conceivably reshape the malignant phenotype.
The potential clinical benefits of reconstituting miRNAs with tumor suppressor function can be gleaned from parallel findings by siRNAs in animal models. Typically, small RNA molecules or transgenes have repeatedly proven to be more robust in terms of consistency of transcript knockdowns as compared with antisense oligonucleotides or ribozymes in achieving loss of function of the targeted offending gene/s (reviewed in Tong et al.
120
), and at threshold concentrations that are several orders of magnitude below typically used antisense oligonucleotides. 121, 122 The efficacy of localized siRNAbased therapeutics is currently being explored in a number of Phase I/II clinical trials. These studies examine local delivery of siRNAs against VEGF and its receptor, VEGF-R1, for exudative, age-related macular degeneration, and the intranasal delivery of siRNA (ALN-RSV01) to specifically inhibit respiratory syncytial virus infection. 123 Other agents are under preclinical development in the arenas of infectious disease (HIV-and HBV-siRNAs), inflammation (IL-4R) and cancer (VEGF).
Emerging evidence indicate that perturbation of miRNA-mediated regulatory pathways can achieve similar in vivo knockdown effects as siRNAs. Introduction of Pol II-mediated, artificial intronic miRNA system against b-catenin or noggin into chicken embryos resulted in long-term (41 month) silencing of the specific gene and a correspondingly altered phenotype. 29 With the use of a plasmid-driven artificial miRNA based on the the murine miR-155 sequence, Li and co-workers 124 demonstrated the in vivo silencing of PRL-3, a protein tyrosine phosphatase, resulting in growth suppression of peritoneal metastases and improved survival of nude mice bearing gastric carcinoma xenografts. Conversely, miRNAs can be inhibited in vitro with specific 2 0 -O-methyl oligonucleotide antagonists (AMOs), [124] [125] [126] or 'antagomirs' when delivered in the form of liposomal complex into adult mice, 56 and conceivably can be used to negate the translational-regulatory effects of 'oncogenic' miRNAs.
Functionality
The multispecific nature of miRNA-based gene regulation is both a strength and a weakness, and dictates that certain minimal criteria should be fulfilled by the miRNA (or antagomir) candidate prior to clinical consideration. First, the putative gene target/s should be defined and independently verified by multiple laboratories, preferably with multiple cell lines and primary tumor tissues of the same histologic type. Since miRNA expression and function are highly dependent on the cellular differentiation stage, the application of miRNA-based treatment should initially be restricted to narrowly defined histopathological stages for each malignancy. Consistent with the development of all novel therapeutics, in vivo safety and efficacy should be well-defined in preclinical animal models.
While no miRNA or antagomir currently fulfills these criteria, differential expression of a number of miRNAs in human tumors has been documented extensively, with some having experimentally verified primary targets (Table 1) . For example, miR-34a, which was downregulated in approximately 36% of 25 primary colon carcinomas, displayed an inverse relationship of expression with the E2F family protein in the HCT 116 and RKO colon cancer lines. The tumor suppressor role of miR-34 has been confirmed in vivo with these tumor xenografts, following p53 activation by low-dose adriamycin. 63 Thus far, E2F-3 remains to be a predicted target for miR-34a. Further studies are required to experimentally validate that miR-34a acts through the E2F signaling pathway.
Conversely, the knockdown of miR-21 represents a potentially promising experimental therapeutic venue. miR-21 expression was upregulated in large numbers of glioblastomas, 53 breast, 55 pancreatic, 127 head and neck, 128 cervical, 56 colorectal, 129,130 ovarian, 52 and hepatocellular 57 primary tumors and cell lines tested. In vitro knockdown of miR-21 led to increased apoptosis and suppressed cell miRNA-based cancer gene therapy AW Tong and J Nemunaitis growth in glioblastoma, 53 breast 55 and hepatocellular carcinomas. 57 The proapoptotic, antitumor activity of miR-21 knockdown was confirmed in vivo by Corsten, 58 where the use of locked nucleic acid-anti-miR-21 oligonucleotides reduced U87 glioblastoma xenograft growth by 470%. This antiglioma effect was further augmented by combined treatment of bystander neural precursor cells with the proapoptotic protein S-TRAIL (secretable variant of tumor-necrosis factor-related apoptosis-inducing ligand), resulting in tumor xenografts eradication.
Similar findings of in vivo efficacy against breast cancer cells have been reported. Treatment with anti-miR-21 oligonucleotides reduced MCF-7 xenograft growth by approximately 50% for up to 2 weeks. 55 With the use of a transfected luciferase reporter gene system, Frankel 131 recently demonstrated the direct targeting of the tumor suppressor PDCD4 (programmed cell death 4), also in the MCF-7 breast cancer line. PDCD4 binding has been confirmed experimentally in colorectal cell lines, 130 where anti-miR-21 treatment resulted in reduced invasion/ metastatic activity. Other validated targets include the tumor suppressor genes TPM1 in MCF-7 cells 54 and PTEN in hepatocellular carcinomas. 57 It is conceivable that miR-21 targets different negative regulators of the PI3K/AKT/mTOR survival pathway. PDCD4 expression is controlled by the mTOR pathway, in which PTEN acts as the PI3K antagonist. TPM1 belongs to the family of TPM proteins that regulate both microfilament organization and anchorage-independent growth, critical components of the cell transformational process. 132 Thus, a likely explanation is that miR-21 modulates apoptotic function via PDCD4, and anchorage dependence via TPM1 within its gene regulatory network in MCF-7 cells.
Other candidates for miRNA-based cancer therapy include members of the let-7 family, 66 miR-17-5p 108 and miR-16, 107 through their capacity to downregulate RAS þ HMGA2, E2F-1 and BCL-2 expression, respectively. A member of the let-7 family, let-7a-3, was recently found to be overexpressed in a minor proportion of human NSCLC cases, and promoted anchorage-independent colony formation in the A549 lung cancer line. These findings contrast the notion that all members of the let-7 gene family exhibit similar, tumor-suppressive activities. 86 Moreover, the functional impact of these miRNAs has not been characterized in vivo, particularly in consideration of the 'context-dependent' miRNAs that are best exemplified by the miR-17-92 cluster. The miR-17-92 cluster displayed oncogenic, antiapoptotic activity in hematopoietic stem cell-derived tumors. However, members of the miR-17-92 cluster exhibited feedback, cancer-suppressive activity in MYC-overexpressing B lymphomas and repressed the protein levels of the transcription factor E2F1 in HeLa cells, 109 reflecting its antiproliferating role in cancers with amplified C-MYC. Yet, in other solid cancers such as small cell lung carcinoma, miR-17-92 cluster is overexpressed and may exerted oncogenic activity by the reduction of PTEN and RB2 tumor suppressor activity. 50 As new technologies continue to develop for identification, expression profiling, target gene validation and manipulation of miRNA expression in vivo, 133 additional miRNA with a defined contribution to the malignant process may be revealed as candidates for novel, cancer therapeutic agents. Alternatively, eligible miRNA candidates of undefined target activity may be uncovered as clinically relevant through differential expression analysis of distinct patient subsets. In a recently initiated miRNA profiling analysis using a multiplex bead-based liquid hybridization technique with 114 miRNA oligonucleotide-probes (mirMASA; microRNA multianalyte suspension array), we have identified a differential miRNA expression in prostatectomy specimens from early chemical relapse prostate cancer patients, as compared with those from patients without clinical relapse for a period of over 10 years. 134 While malignant tissues from both clinical subsets displayed significantly reduced expression of 5 miRNAs (mir-23b, -100, -145, -221 and -222) according to mirMASA and quantitative, real-time PCR analyses, patients with chemical relapse (postsurgery elevation of prostate-specific antigen) displayed a distinct expression profile of 16 miRNAs, including a lower level of miR-122a. These findings, when coupled with in silico prediction of miRNA targets and functional validation, can be used to identify miRNA candidates whose altered function contributes to prostate cancer progression.
Other epidemiology correlations of miRNA expression profiles with specific biopathologic features have been described. Colon cancers that were characterized by microsatellite stability displayed a distinct miRNA gene expression profile from the histopathologically and clinically distinct subset with high microsatellite instability, particularly in reference to members of the oncogenic miR-17-92 family. 135 The expression of miR-92, miR-20, and miR-18 was also inversely correlated with the differentiative stage of hepatocellular carcinomas. 136 For breast cancers, miR-30 family overexpression was associated with estrogen/progesterone receptor expression. 51 miR-10b expression was intricately linked to potent prometastatic features in breast cancer cells, according to the recent elegant findings of Ma et al. 46 Ectopic miR-10b expression can drive tumor invasion and metastasis in otherwise nonmetastatic breast tumors in vitro and in vivo. miR-10b was experimentally shown to downregulate the translation of homeobox D10 (HOXD10), which in turn led to robust expression of the downstream, previously repressed genes involved in cell migration and extracellular matrix remodeling such as RHOC. These and other findings suggest that an elevated miR-10b may be a unique feature of the pro-metastatic breast cancer subset, 137 although it remains to be established whether silencing of miR-10b can reverse the metastatic phenotype of highly malignant breast cancer cells in vivo.
Delivery
As in all other forms of cancer gene therapy platforms, the manner by which the reconstituting miRNA or antagomir is delivered is likely to critically impact success of the experimental approach (Table 2 ). For cancer miRNA-based cancer gene therapy AW Tong and J Nemunaitis patients with advanced disease, multiorgan metastatic foci are largely responsible for the morbidity and mortality. Hence, the effective and global systemic coverage of target cells represents a critical factor for optimizing therapeutic outcome. Experimental strategy remains to be defined for the stable transfection miRNAs and for achieving prolonged knockdown. On the basis of animal studies on siRNA delivery and the parallel biologic features of siRNA and miRNAs, the two potentially applicable systemic delivery modes for small RNA transgenes are viral vectors 138, 139 and nonviral, lipid-based (cationic liposomes, liposome-protamine/DNA) particles [140] [141] [142] ( Table 2) .
Late-generation adenoviral constructs are 'reengineered' to replicate selectively in cancer cells with defined cytogenetic defects (p53 and pRb) through modification of viral promoter/enhancer elements. The oncolytic adenovirus is activated only by nuclear transcriptional factor/s that are unique or upregulated in the cancer cell, and has produced significant clinical gains as a stand-alone agent or in combination with conventional chemotherapy. 143 We recently demonstrated that incorporation of a K-ras v12 -specific siRNA hairpin construct into the deleted E3b region of the late-generation, oncolytic adenovirus ONYX-411 led to a 10-fold increased antitumor potency in human lung cancer cells expressing the relevant K-ras v12 mutation. This construct was markedly more effective in reducing the growth of subcutaneous H79 pancreatic cancer xenografts than parental ONYX-411, 144 indicating that ras oncogene suppression and viral oncolysis can generate a two-pronged attack on tumor cell growth. Alternatively, cell-specific immunoliposomes, which have been used successfully to deliver chemotherapy drug by target-specific cell surface receptors, may also be a viable small RNA delivery platform. 145, 146 According to Chang and coworkers, 147 a nanoscale nonviral liposome-based complex incorporating the targeting moiety of an antitransferrin receptor single-chain antibody fragment can efficiently and specifically deliver siRNA to both primary and metastatic disease sites. It should be noted, however, that TLR (Toll-like receptor)-9 activation and inflammatory cytokine induction by lipoplexed oligonucleotides may countermand the intended gene-specific outcomes of systemic, small RNA delivery. 148 
Nonspecific toxicity
Recently, Kay and coworkers 149 found that sustained, high-level short hairpin (shRNA) expression produced lethal, dose-dependent liver injury. Morbidity was associated with the downregulation of liver-derived miRNAs, which may reflect the displacement of endogenous miRNA precursor processing events by the exogenously introduced shRNAs, a likely candidate being the nuclear transport component karyopherin exportin-5. AGO2, the 'slicer' enzyme in mammalian RISC that cleaves the target mRNA, was recently found to be the main limiting factor downstream of exportin-5. 150 The combined Ago2-and exportin-5-transfected mice demonstrated markedly improved RNAi activity and reduced liver toxicity than singly transfected animals. The risk of oversaturating endogenous small RNA pathways may be minimized by optimizing shRNA dose and sequence. Alternatively, siRNAs have been integrated into artificial miRNA shuttles or embedded into the molecular context of an miRNA, a maneuver that apparently lowered nonspecific toxicity and improved RNAi efficiency. 151, 152 These are preliminary findings to suggest that heretofore undetermined feedback mechanisms in the cellular processing, and effector miRNA machinery may provide a measure of safety that is unavailable for exogenous, artificial siRNAs.
Immune activation
The global upregulation of IFN (interferon)-stimulated genes 140, 153 and inflammatory cytokines is a major component of the 'off-target activity' following siRNA administration both in vivo in mice and in vitro in human blood. 154 In most studies, the IFN-inducing activities were not only primarily attributable to innate immune activation by the delivery vehicle, 10, 148, 155 but may also depend on the presence or absence of immunostimulatory motifs in the artificially designed siRNAs. 154 There is currently limited evidence to indicate whether exogenously introduced miRNAs (with wild-type sequence) may similarly elicit immune-activating 'danger signals.' According to Epanchintsev, 156 introduction of the relevant miRNA by a plasmid vector effectively knocked down p53 expression, but neither nonsilencing control nor the p53-specific miRNA elicited an IFN response in U20S osteosarcoma cells. In the study by Grimm et al., 149 where mice died following intravenous injection of shRNAexpressing viral vectors, inflammatory cytokines were not 153 This consideration emphasizes the need to identify the most potent miRNA candidate that can impact tumor cell growth and to work with the lowest concentration possible.
The multispecific nature of miRNA gene regulation adds a unique layer of complexity with respect to the interplay of tumor growth-regulation and immune-activating activities. For example, miR-155, encoded from the third exon of the BIC (B-cell integration cluster) oncogene, was overexpressed in multiple tumor cell types 66, 51, 74 and has demonstrated oncogenic activity. While the knockdown of miR-155 presents a potentially attractive therapeutic venue, systemic loss of miR-155 activity may collaterally affect immune proficiency, as this miRNA has been found to play important roles in modulating TLR-or IFNb-mediated innate immune responses, 157 and T-, B-and dendritic cell functions.
158,159
The use of tumor-specific delivery agents, such as viral vectors or tumor-targeted nanoparticles, could conceivably obviate this concern. An improved understanding of the universe of miRNA-regulated gene networks may address the intriguing possibility of uncovering therapeutic candidates that conceivably achieve parallel, beneficial tumor inhibitory and immune-activating outcomes.
Conclusion
MicroRNA dysregulation is the common outcome of multiple genetic and epigenetic events, including genomic instability, epigenetic regulatory defects and/or intrinsic defects in the miRNA processing and effector cellular pathways. The loss of key, miRNA-mediated posttranscriptional regulatory activity appears to critically weaken the intricate balance of oncogene and tumor suppressor network functions, thereby contributing to oncogenesis and cancer progression. An extension of these findings is to consider the reconstitution of tumor-suppressive miRNAs or the knockdown of overexpressed, oncogenic miRNAs as a means of harnessing nature's extraordinarily efficient and rapid way of regulating gene expression. Eligible miRNA candidates in these regards have recently emerged. Not withstanding the consideration of multispecificity, functional analysis indicates that individual miRNAs only negatively regulate a small number of dominant mRNA targets in a particular cancer cell type. This premise needs to be validated through detailed screening with cancer cells of the relevant histotype and/ or the use of an appropriate delivery agent that limits the expression of the miRNA transgene to the tumor microenvironment. Thus far, in vivo validation of individual miRNA-based approaches has been limited. Yet given the groundwork from preexisting, siRNA studies, speedy progress can be anticipated in defining the clinical applicability of miRNA-based cancer gene therapy approaches. Through miRNA differential expression analysis on patients with distinct clinicopathological features, additional miRNA candidates that modulate more than one critical cancer pathway node may also be uncovered.
